Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Internal Medicine, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria.
Gut Microbes. 2023 Dec;15(2):2267185. doi: 10.1080/19490976.2023.2267185. Epub 2023 Oct 10.
Wang K. et al. introduced the concept of Microbial-Host isozymes (MHIs) and highlighted their role in mediating microbiota-host interactions. They identified bacterial-derived DPP4 as an isoenzyme affecting glucose tolerance and showed that host DPP4 inhibitors may not effectively target bacterial DPP4. They developed an MHI screen system, identifying 71 MHIs in healthy gut microbiota. Among them, DPP4 isozymes degrade GLP-1, explaining variable responses to sitagliptin. This breakthrough opens new avenues for metabolic disorder treatment. However, the complex nature of gut symbiotic bacteria requires further research to understand MHI mechanisms, regulatory roles, and interactions with the host. Precise interventions in gut microbiota offer personalized approaches to metabolic diseases.
王 K. 等人引入了微生物-宿主同工酶（Microbial-Host isozymes，MHIs）的概念，并强调了它们在介导微生物群落-宿主相互作用中的作用。他们发现细菌衍生的 DPP4 是一种影响葡萄糖耐量的同工酶，并表明宿主 DPP4 抑制剂可能无法有效靶向细菌 DPP4。他们开发了一种 MHI 筛选系统，在健康肠道微生物群中鉴定出 71 种 MHI。其中，DPP4 同工酶降解 GLP-1，解释了对西他列汀反应的变异性。这一突破为代谢紊乱的治疗开辟了新途径。然而，肠道共生细菌的复杂性要求进一步研究以了解 MHI 机制、调节作用以及与宿主的相互作用。对肠道微生物群的精确干预为代谢疾病提供了个性化的治疗方法。
